BioSpace News Archive

AbbVie’s Humira Loses Only 4% of Market Share to Biosimilars: Report

Even with discounts that reach as high as 86%, Humira biosimilars are finding it difficult to take market share away from the AbbVie blockbuster, according to a new report from Samsung Bioepis.

April 9, 2024
·
2 min read
·
Tristan Manalac
Business

Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs

A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.

April 9, 2024
·
2 min read
·
Nick Paul Taylor
Deals

7 Billion-Dollar Oncology M&As from Q1

AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain hot.

April 9, 2024
·
4 min read
·
Neil Versel
Drug Delivery

The IRA Is Already Curtailing Small Molecule Drug Development. Here’s How to Reverse That.

Many promising small molecules have lost significant investment appeal as a result of lopsided incentives favoring biologics in 2022’s Inflation Reduction Act.

April 9, 2024
·
4 min read
·
John Stanford
Policy

EMA to Review Diabetes and Weight-Loss Drugs for Suicidal Ideation Risk

As part of its ongoing review, the European Medicines Agency this week is slated to examine the potential risks of suicidal ideation and self-harm associated with diabetes and weight-loss treatments.

April 9, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data

Pfizer’s respiratory syncytial virus vaccine Abrysvo is just as effective in younger adults aged 18 to 59 years as it is in the shot’s currently approved population of 60 years of age and older.

April 9, 2024
·
2 min read
·
Tristan Manalac
Drug Development

FDA Backs BrainStorm’s Design for Phase IIIb Trial in Early-Stage ALS

After BrainStorm Cell Therapeutics withdrew its BLA in October 2023 for NurOwn, the company announced Tuesday that the FDA has agreed to the design of a Phase IIIb trial for its amyotrophic lateral sclerosis candidate under a Special Protocol Assessment.

April 9, 2024
·
2 min read
·
Kate Goodwin
Job Trends

Top 5 Companies Hiring in San Diego

Looking for a biopharma job in San Diego? Check out these top five companies hiring life sciences professionals like you.

April 9, 2024
·
1 min read
·
Angela Gabriel
Alphabet Soup: AACR and ACC Dominate Headlines This Week

Plus, how the geopolitical tensions with China will affect U.S. biopharma

April 9, 2024
·
1 min read
·
Greg Slabodkin, Heather McKenzie, Tyler Patchen
Business

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET.

April 9, 2024
·
2 min read